Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis

de Vries, Folgerdiena M.; Kolthof, Johan; Postma, Maarten J.; Denig, Petra; Hak, Eelko
November 2014
PLoS ONE;Nov2014, Vol. 9 Issue 11, p1
Academic Journal
Aims: To estimate the efficacy of standard and intensive statin treatment in the secondary prevention of major cardiovascular and cerebrovascular events in diabetes patients. Methods: A systematic search was conducted in Medline over the years 1990 to September 2013. Randomized, double-blind, clinical trials comparing a standard-dose statin with placebo or a standard-dose statin with an intensive-dose statin for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients were selected. Trial and patient characteristics were extracted independently by two researchers. The combined effect on the composite primary endpoint was measured with a fixed-effect model. Potential publication bias was examined with a funnel plot. Results: Five trials were included in the analysis comparing standard-dose statins with placebo with a total of 4 351 participants. Four trials were included for comparing standard-dose with intensive-dose statins, including 4 805 participants. Compared with placebo, standard-dose statin treatment resulted in a significant relative risk (RR) reduction of 15% in the occurrence of any major cardiovascular or cerebrovascular event (RR 0.85, 95% CI 0.79–0.91). Compared with standard-dose statin treatment, intensive-dose statin treatment resulted in an additional 9% relative risk reduction (RR 0.91, 95% CI 0.84–0.98). Conclusion: Treatment with standard-dose statins to prevent cardiovascular or cerebrovascular events in diabetes patients with manifest cardiovascular disease results in an estimated 15% relative risk reduction and intensive-dose statin treatment adds 9%. If proven cost-effective, more intensive statin treatment should be recommended for diabetes patients at high cardiovascular risk.


Related Articles

  • Statin therapy for cardiovascular disease. Thomas, Susan // Practice Nurse;11/23/2007, Vol. 34 Issue 9, p34 

    The article considers statin therapy for cardiovascular disease. Research has shown that statins reduce the risk of cardiovascular events in primary and secondary prevention. The five statins currently licensed for use in Great Britain are simvastatin, atorvastatin, fluvastatin, pravastatin, and...

  • Statins Impair Glucose Uptake in Tumor Cells. Malenda, Agata; Skrobanska, Anna; Issat, Tadeusz; Winiarska, Magdalena; Bil, Jacek; Oleszczak, Bozenna; Sinski, Maciej; Firczuk, Malgorzata; Bujnicki, Janusz M.; Chlebowska, Justyna; Staruch, Adam D.; Glodkowska-Mrowka, Eliza; Kunikowska, Jolanta; Krolicki, Leszek; Szablewski, Leszek; Gaciong, Zbigniew; Koziak, Katarzyna; Jakobisiak, Marek; Golab, Jakub; Nowis, Dominika A. // Neoplasia;Apr2012, Vol. 14 Issue 4, p311 

    Statins, HMG-CoA reductase inhibitors, are used in the prevention and treatment of cardiovascular diseases owing to their lipid-lowering effects. Previous studies revealed that, by modulating membrane cholesterol content, statins could induce conformational changes in cluster of differentiation...

  • Statins, Primary Prevention, and Overall Mortality. Prasad, Vinay // Annals of Internal Medicine;6/17/2014, Vol. 160 Issue 12, p867 

    The author discusses the significance of statins in the primary prevention of cardiovascular disease and effects of the treatment on the overall mortality. Topics discussed include variation in the outcomes between patients receiving statins and placebo, inclusion of patients with angina and...

  • Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer. Lee, S J; Lee, I; Lee, J; Park, C; Kang, W K // British Journal of Cancer;7/29/2014, Vol. 111 Issue 3, p497 

    Background:Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are commonly prescribed because of their therapeutic and preventive effects on cardiovascular diseases. Even though they have been occasionally reported to have antitumour activity, it is unknown whether statins have...

  • Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus? Hackam, Daniel G. // CMAJ: Canadian Medical Association Journal;10/12/2004, Vol. 171 Issue 8, p857 

    Presents a study on the use of statins in preventing cardiovascular disease (CVD) in patients with type 2 diabetes. Procedures of the study; Factors that should be considered by clinicians for those without CVD; Effects of statins on the patients.

  • Statins in the Primary and Secondary Prevention of Cardiovascular Disease in Women. Virani, Salim S. // Texas Heart Institute Journal;2013, Vol. 40 Issue 3, p288 

    The article examines the growing use of statins in the primary and secondary prevention of cardiovascular disease (CVD) in women. The author explores the CVD risks associated with several lipid fractions in men and women. The author discusses the results of the meta-analysis commissioned by the...

  • NICE sticks to decision to offer statins to millions more people. Price, Caroline // Pulse;Aug2014, p20 

    The article reports on the primary prevention plans for cardiovascular disease (CVD) recommended by the National Institute for Health and Care Excellence (NICE). Among the aspects in the recommendations include the tools to assess the CVD risk, the prescription of statins drug, and the...

  • Should statins be used for primary prevention in the elderly?  // PharmacoEconomics & Outcomes News;May2015, Vol. 727 Issue 1, p29 

    The article discusses research being done on the cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease in older adults in the U.S. It references a study by M. C. Odden et al. published in the April 12, 2015 issue of the "Annals of Internal Medicine."...

  • Increased risk of glucose intolerance and type 2 diabetes with statins: In people with a moderate or high risk of cardiovascular disease, benefits of statins still outweigh the risks. Byrne, Christopher D.; Wild, Sarah H. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/15/2011, Vol. 343 Issue 7827, p755 

    The article focuses on a clinical review which states that the drug statins causes type 2 diabetes and worsens glucose tolerance. It informs that the 4278 people out of 91 140 developed diabetes during four years of statins exposure. It also informs that an analysis of 2001 West of Scotland...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics